Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2003 | 1 |
2004 | 2 |
2025 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S80-4. doi: 10.1097/01.fjc.0000166207.74178.d0.
J Cardiovasc Pharmacol. 2004.
PMID: 15838366
Clinical Trial.
Sitaxsentan therapy for pulmonary arterial hypertension.
Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR; STRIDE-1 Study Group.
Barst RJ, et al.
Am J Respir Crit Care Med. 2004 Feb 15;169(4):441-7. doi: 10.1164/rccm.200307-957OC. Epub 2003 Nov 20.
Am J Respir Crit Care Med. 2004.
PMID: 14630619
Clinical Trial.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.